Nanovi, specialized in the development of advanced biomaterials for use in the radiotherapy of cancer, has secured EUR 2.7M from current investors to bring BioXmark technology to the market.
BioXmark is a novel injectable liquid tissue marker which improves the accuracy and quality of radiation therapy and will be available for commercial use in Europe during the first half of 2015.
Jesper Roested, Investment Director, Vækstfonden says: “We are very pleased to see Nanovi progress in bringing BioXmark to the market, and we look forward to continue our close collaboration to help transforming Nanovi to a commercial company.“
Nanovi moreover brings two new board members to the company: Flemming Thorup, President and CEO of 3Shape A/S since 2001, who will serve as the Chairman of the Board of Directors, and Gordon McVie, MD, professor and an international authority on the treatment and research of cancer who will serve as a member of the Board of Directors.
Morten Albrechtsen, CEO and co-founder of Nanovi says: “We are happy to welcome two new board members. Flemming Thorup brings distinctive skills on how to successfully commercialize and grow a medical company internationally, and Gordon McVie brings unmatched clinical understanding essential for successful commercialization of BioXmark. We are also very pleased for the continued support and good collaboration with our investors, which keep our plan on-track and enables us to bring BioXmark to the marked already next year.”